Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 5/2018

Open Access 01-09-2018 | Original Article

Hepatocellular carcinoma in Gaucher disease: an international case series

Authors: Martine Regenboog, Laura van Dussen, Joanne Verheij, Neal J. Weinreb, David Santosa, Stephan vom Dahl, Dieter Häussinger, Meike N. Müller, Ali Canbay, Miriam Rigoldi, Alberto Piperno, Tama Dinur, Ari Zimran, Pramod K. Mistry, Karima Yousfi Salah, Nadia Belmatoug, David J. Kuter, Carla E. M. Hollak

Published in: Journal of Inherited Metabolic Disease | Issue 5/2018

Login to get access

Abstract

Gaucher disease (GD) is associated with an increased risk for malignancies. Next to hematological malignancies, the development of solid tumors in several organs has been described. The liver is one of the major storage sites involved in GD pathogenesis, and is also affected by liver-specific complications. In this case series, we describe 16 GD type 1 (GD1) patients from eight different referral centers around the world who developed hepatocellular carcinoma (HCC). Potential factors contributing to the increased HCC risk in GD patients are studied. Eleven patients had undergone a splenectomy in the past. Liver cirrhosis, one of the main risk factors for the development of HCC, was present in nine out of 14 patients for whom data was available. Three out of seven examined patients showed a transferrin saturation > 45%. In these three patients the presence of iron overload after histopathological examination of the liver was shown. Chronic hepatitis C infection was present in three of 14 examined cases. We summarized all findings and made a comparison to the literature. We recommend that GD patients, especially those with prior splenectomy or iron overload, be evaluated for signs of liver fibrosis and if found to be monitored for HCC development.
Literature
go back to reference Arends M, Van Dussen L, Biegstraaten M, Hollak CE (2013) Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol 161:832–842CrossRefPubMed Arends M, Van Dussen L, Biegstraaten M, Hollak CE (2013) Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol 161:832–842CrossRefPubMed
go back to reference Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324:1464–1470CrossRefPubMed Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324:1464–1470CrossRefPubMed
go back to reference Bohte AE, Van Dussen L, Akkerman EM et al (2013) Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One 8(3):e57507CrossRefPubMedPubMedCentral Bohte AE, Van Dussen L, Akkerman EM et al (2013) Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One 8(3):e57507CrossRefPubMedPubMedCentral
go back to reference Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of glucocerebrosides. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun 18:221–225CrossRefPubMed Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of glucocerebrosides. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun 18:221–225CrossRefPubMed
go back to reference Breiden-Langen CM, Büchsel R, Brambs HJ, Oehlert M, Matern S (1991) Coincidence of Gaucher disease with primary hepatocellular carcinoma. Leber Magen Darm 21:129–130 Breiden-Langen CM, Büchsel R, Brambs HJ, Oehlert M, Matern S (1991) Coincidence of Gaucher disease with primary hepatocellular carcinoma. Leber Magen Darm 21:129–130
go back to reference Cox TM, Drehlichman G, Cravo R et al (2015) Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 385(9985):2355–2362CrossRefPubMed Cox TM, Drehlichman G, Cravo R et al (2015) Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 385(9985):2355–2362CrossRefPubMed
go back to reference De Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Häussinger D, Hollak CE (2006) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36:53–58CrossRefPubMed De Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Häussinger D, Hollak CE (2006) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36:53–58CrossRefPubMed
go back to reference Degasperi E, Colombo M (2016) Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 1:156–164CrossRefPubMed Degasperi E, Colombo M (2016) Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 1:156–164CrossRefPubMed
go back to reference Diáz-González A, Forner A (2016) Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 30:1001–1010CrossRefPubMed Diáz-González A, Forner A (2016) Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 30:1001–1010CrossRefPubMed
go back to reference EASL-EORTC clinical practice guidelines (2012) Management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef EASL-EORTC clinical practice guidelines (2012) Management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef
go back to reference El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460–468CrossRefPubMed El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460–468CrossRefPubMed
go back to reference Erjavec Z, Hollak CE, de Vries EG (1999) Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Ann Oncol 10:243CrossRefPubMed Erjavec Z, Hollak CE, de Vries EG (1999) Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Ann Oncol 10:243CrossRefPubMed
go back to reference Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50CrossRefPubMed Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50CrossRefPubMed
go back to reference Fleshner PR, Aufses AH, Grabowski GA, Elias R (1991) A 27-year experience with splenectomy for Gaucher’s disease. Am J Surg 161:69–75CrossRefPubMed Fleshner PR, Aufses AH, Grabowski GA, Elias R (1991) A 27-year experience with splenectomy for Gaucher’s disease. Am J Surg 161:69–75CrossRefPubMed
go back to reference Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet 372:1263–1271CrossRefPubMed Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet 372:1263–1271CrossRefPubMed
go back to reference Guo L, Zheng L, Hu L, Zhou H, Yu L, Liang W (2017) Transient Elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients. Med Sci Monit 23:5106–5112CrossRefPubMedPubMedCentral Guo L, Zheng L, Hu L, Zhou H, Yu L, Liang W (2017) Transient Elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients. Med Sci Monit 23:5106–5112CrossRefPubMedPubMedCentral
go back to reference James SP, Stromeyer FW, Chang C, Barranger JA (1981) Liver abnormalities in patients with Gaucher’s disease. Gastroenterology 80:126–133CrossRefPubMed James SP, Stromeyer FW, Chang C, Barranger JA (1981) Liver abnormalities in patients with Gaucher’s disease. Gastroenterology 80:126–133CrossRefPubMed
go back to reference Kowdley KV (2004) Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127:S79–S86CrossRefPubMed Kowdley KV (2004) Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127:S79–S86CrossRefPubMed
go back to reference Lachmann RH, Wight DG, Lomas DJ, Fisher NC, Schofield JP, Elias E, Cox TM (2000) Massive hepatic fibrosis in Gaucher’s disease: clinic-pathological and radiological features. Q J Med 93:237–244CrossRef Lachmann RH, Wight DG, Lomas DJ, Fisher NC, Schofield JP, Elias E, Cox TM (2000) Massive hepatic fibrosis in Gaucher’s disease: clinic-pathological and radiological features. Q J Med 93:237–244CrossRef
go back to reference Lee RE (1982) The pathology of Gaucher disease. Prog Clin Biol Res 95:177–217PubMed Lee RE (1982) The pathology of Gaucher disease. Prog Clin Biol Res 95:177–217PubMed
go back to reference Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK (2010) Expanding spectrum of the association between type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types – correlation with genotype and phenotype. Am J Hematol 85:340–345PubMedPubMedCentral Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK (2010) Expanding spectrum of the association between type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types – correlation with genotype and phenotype. Am J Hematol 85:340–345PubMedPubMedCentral
go back to reference Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS (2005) Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42:218–224CrossRefPubMed Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS (2005) Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42:218–224CrossRefPubMed
go back to reference Mistry PK, Taddei T, Vom Dahl S, Rosenbloom BE (2013) Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog 18:235–246CrossRefPubMedPubMedCentral Mistry PK, Taddei T, Vom Dahl S, Rosenbloom BE (2013) Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog 18:235–246CrossRefPubMedPubMedCentral
go back to reference Nakanuma Y, Unoura M, Noto H, Ohta G (1986) Human chorionic gonadotropin in primary liver carcinoma in adults. An immunohistochemical study. Virch Arch A Pathol Anat Histopathol 409:365–373CrossRef Nakanuma Y, Unoura M, Noto H, Ohta G (1986) Human chorionic gonadotropin in primary liver carcinoma in adults. An immunohistochemical study. Virch Arch A Pathol Anat Histopathol 409:365–373CrossRef
go back to reference Perel Y, Bioulac-Sage P, Chateil JF, Trillaud H, Carles J, Lamireau T, Guillard JM (2002) Gaucher’s disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy. Pediatrics 109:1170CrossRefPubMed Perel Y, Bioulac-Sage P, Chateil JF, Trillaud H, Carles J, Lamireau T, Guillard JM (2002) Gaucher’s disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy. Pediatrics 109:1170CrossRefPubMed
go back to reference Regenboog M, Bohte AE, Akkerman EM, Stoker J, Hollak CEM (2017) Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment. Br J Haematol. https://doi.org/10.1111/bjh.14915 Regenboog M, Bohte AE, Akkerman EM, Stoker J, Hollak CEM (2017) Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment. Br J Haematol. https://​doi.​org/​10.​1111/​bjh.​14915
go back to reference Schütte K, Schulz C, Poranzke J et al (2014) Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol 14:117CrossRefPubMedPubMedCentral Schütte K, Schulz C, Poranzke J et al (2014) Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol 14:117CrossRefPubMedPubMedCentral
go back to reference Shiran A, Brenner B, Laor A, Tatarsky I (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72:219–224CrossRefPubMed Shiran A, Brenner B, Laor A, Tatarsky I (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72:219–224CrossRefPubMed
go back to reference Taddei TH, Kacena KA, Yang M et al (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84:208–214CrossRefPubMedPubMedCentral Taddei TH, Kacena KA, Yang M et al (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84:208–214CrossRefPubMedPubMedCentral
go back to reference Van Meer S, van Erpecum KJ, Sprengers D et al (2016) Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol 28:352–359CrossRefPubMed Van Meer S, van Erpecum KJ, Sprengers D et al (2016) Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol 28:352–359CrossRefPubMed
go back to reference Weinreb NJ, Goldblatt J, Villalobos J et al (2013) Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 36:543–553CrossRefPubMed Weinreb NJ, Goldblatt J, Villalobos J et al (2013) Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 36:543–553CrossRefPubMed
go back to reference Weinreb NJ, Lee RE (2013) Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy. Crit Rev Oncog 18:177–195CrossRefPubMed Weinreb NJ, Lee RE (2013) Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy. Crit Rev Oncog 18:177–195CrossRefPubMed
go back to reference Wood JC (2014) Guidelines for quantifying iron overload. Hematol Am Soc Hematol Educ Program 1:210–215CrossRef Wood JC (2014) Guidelines for quantifying iron overload. Hematol Am Soc Hematol Educ Program 1:210–215CrossRef
go back to reference Xu R, Mistry P, Mckenna G et al (2005) Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Semin Liver Dis 25:226–229CrossRefPubMed Xu R, Mistry P, Mckenna G et al (2005) Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Semin Liver Dis 25:226–229CrossRefPubMed
go back to reference Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34:197–200CrossRefPubMed Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34:197–200CrossRefPubMed
Metadata
Title
Hepatocellular carcinoma in Gaucher disease: an international case series
Authors
Martine Regenboog
Laura van Dussen
Joanne Verheij
Neal J. Weinreb
David Santosa
Stephan vom Dahl
Dieter Häussinger
Meike N. Müller
Ali Canbay
Miriam Rigoldi
Alberto Piperno
Tama Dinur
Ari Zimran
Pramod K. Mistry
Karima Yousfi Salah
Nadia Belmatoug
David J. Kuter
Carla E. M. Hollak
Publication date
01-09-2018
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 5/2018
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-018-0142-y

Other articles of this Issue 5/2018

Journal of Inherited Metabolic Disease 5/2018 Go to the issue